BridgeBio Pharma vs Biomarin Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BridgeBio Pharma Inc (BBIO)

Q3 202622 Jun – 4 Sep 2026

▲3

BridgeBio Soars on Rival's Failure and Strong Attruby Data

AstraZeneca's ATTR-CM failure clears path for Attruby AstraZeneca's heart drug failed, removing a key competitor for BridgeBio's Attruby. Shares jumped 15% to a 52-week high as investors saw a clearer market for the treatment.
This was the main catalyst for the stock's rise in the quarter.
Attruby shows kidney benefits and strong revenue growth Attruby demonstrated kidney-protective benefits, and Q2 revenue surged 120% to $243.7 million. Imaging data also hinted at possible cardiac improvement, though that finding is exploratory.
These clinical and financial results reinforced the growth story.
Pipeline advances with three late-stage drugs nearing launch Three late-stage drugs are close to launch, two under FDA Priority Review. Infigratinib's Phase 3 data were published in NEJM, boosting confidence in the company's pipeline.
Pipeline progress supports future revenue potential.
Capital raise and Medicaid pricing deal create trade-offs BridgeBio raised $1 billion in preferred equity, strengthening its balance sheet. However, a Medicaid most-favored-nation pricing deal could reduce future U.S. revenue per prescription.
The capital boost is positive, but the pricing deal poses a risk to future profits.

August 202610 Aug – 4 Sep 2026

▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.
This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.
Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.
Pipeline launches are the next major growth catalyst and explain why investors look past current losses.
New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.
This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.
BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.
This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

Latest10 Aug – 4 Sep 2026

▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.
This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.
Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.
Pipeline launches are the next major growth catalyst and explain why investors look past current losses.
New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.
This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.
BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.
This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

July 202622 Jun – 10 Jul 2026

▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.
This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.
New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.
This new clinical evidence differentiates Attruby from competitors and could drive future demand.
BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.
This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.
Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.
This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

22 Jun – 10 Jul 2026

▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.
This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.
New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.
This new clinical evidence differentiates Attruby from competitors and could drive future demand.
BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.
This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.
Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.
This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

Biomarin Pharmaceutical Inc (BMRN)

Q3 202623 Jun – 30 Sep 2026

▲4

BioMarin advances Voxzogo, adds Alesta, settles patent, raises guidance

Voxzogo nears full FDA approval and $1B revenue Voxzogo moved toward full FDA approval, with a decision expected February 2027, and approached $1 billion in annual revenue. Positive Phase 3 data in hypochondroplasia supports a filing to expand its label.
Voxzogo is BioMarin's key growth driver, and its regulatory and commercial progress directly boosts investor confidence.
Alesta acquisition adds oral hypophosphatasia therapy BioMarin acquired Alesta, gaining ALE1, a potential first oral treatment for hypophosphatasia. The deal expands the pipeline into a new rare disease area, though ALE1 remains unproven.
The acquisition adds a new pipeline asset and strategic growth opportunity, which can lift investor sentiment.
Patent settlement with Ascendis secures royalties BioMarin settled patent litigation with Ascendis, securing royalties on rival Yuviwel through 2030. This removes legal uncertainty and provides a finite but predictable revenue stream.
The settlement eliminates a legal overhang and adds royalty income, improving financial visibility.
Raised guidance and Amicus synergies improve outlook BioMarin raised its financial guidance, targeted $200 million in annual savings from Amicus synergies, and accelerated deleveraging. An AI enzyme partnership with Profluent adds long-term pipeline potential.
These financial and strategic moves strengthen the company's outlook and support the stock.

September 202631 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

Latest31 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

July 202623 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

23 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.